Genmab — April 2026

[E_L]

makes you wonder if hexabody-cd38 really was completely without residual
value...

[Solsen]

You have a point !

[Solsen]

Lilly går all in i Myeloma med en M&A på et fase 1 stof med upfront på $3,25 https://www.morningstar.com/news/dow-jones/202604204694/eli-lilly-to-buy-kelonia-therapeutics-for-initial-325-billion-update

[E_L]

Epcoritamab Plus Lenalidomide and Rituximab in Practice: A Focus on EPCORE FL-1 https://www.pharmacytimes.com/view/epcoritamab-plus-lenalidomide-and-rituximab-in-practice-a-focus-on-epcore-fl-1

[Bulder]

E L 17.47, it was a complete scandal that
Genmab dropped it. Erzo-gate.

[Sukkeralf]

3 år siden Genmab lavede aftalen med Argenx - mon vi snart hører om det fører til noget. Synes ikke ret mange af de samarbejder de laver har ført noget med sig. BioNTech samarbejdet givet en del kliniske kandidater, men ellers har de været sløjt.

[E_L]

'Erzo-gate'

[Peter_Panik]

Hvornår mon Genmab har tænkt sig at stige igen. De fine Darzalex tal er jo allerede udvisket.. Virker ikke tiol den store interesse i aktien mere.

[concillado]

Bare rolig til sommer falder den typisk yderligere i agurketiden

[concillado]

Hvis man tror på det fundamentale i aktien, så er lavinteresse-perioder blot perfekte opkøbsmuligheder.

[Bella1]

Efterhånden er der vist tale om helårsagurker...

[E_L]

Teclistamab on the CHMP agenda : Scope: Extension of indication to include in combination with daratumumab treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior therapy for TECVAYLI

[E_L]

this is a nice new trial! : Study to Assess the Efficacy and Safety of Rina-S in Participants With Advanced Gastrointestinal (GI) Cancers (RAINFOL-09) https://clinicaltrials.gov/study/NCT07539311

[E_L]

so they
have a RAINFOL-01 - 05 and 09, but no 6, 7, 8...? is that correct?

[Raun]

Der er i hvert fald ikke meget om 06 og 07 - Slet ikke om 08: RAINFOL-06 & 07: Disse forventes at dække yderligere kombinationsbehandlinger eller nye sygdomsområder (indikationer), hvor Folat Receptor alfa (FRα) er udtrykt.
Genmab har indikeret, at de vil udforske Rina-S i kombination med andre terapier (som f.eks. immunterapi eller andre målrettede midler) for at flytte behandlingen tidligere ind i sygdomsforløbet.

[E_L]

asco abstract titles are out, i see for peto, rina-s, tiso and epco, but they make it very hard to copy/paste. titles only for now, text
in May

[E_L]

you can search ASCO 2026 via https://meetings.asco.org/meetings/2026-asco-annual-meeting/335/program-guide/scheduled-sessions/search?q=epcoritamab

[E_L]

ideally we'll get a late breaking Epco abstract, but we'll see

[E_L]

@Raun did you find any info there on Rainfol 6 /7 or is that some AI generated stuff...?

[Raun]

Det er AI: Genmab's strategic investor materials and recent pipeline updates indicate plans to expand Rina-S (Rinatabart Sesutecan) studies, including anticipated developments in late-stage portfolios that likely cover combinations such as RAINFOL-06 and 07. These materials indicate a focus on assessing Rina-S in combination with bevacizumab or immunotherapy, building on data from the RAINFOL-01 trial